<DOC>
	<DOCNO>NCT00057954</DOCNO>
	<brief_summary>RATIONALE : Photopheresis allow patient white blood cell treat ultraviolet ( UV ) light drug outside body inactivate T cell . Pentostatin may suppress immune system reduce chance develop graft-versus-host disease ( GVHD ) follow bone marrow transplantation . Combining photopheresis pentostatin total-body irradiation may effective kill cancer cell bone marrow transplantation . PURPOSE : This phase II trial study well give photophoresis together pentostatin total-body irradiation reduced-intensity regimen allogeneic bone marrow transplantation work treat patient relapse non-Hodgkin 's Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Reduced-Intensity Regimen Before Allogeneic Transplant Patients With Relapsed Non-Hodgkin 's Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine rate stable engraftment donor cell patient relapse non-Hodgkin 's Hodgkin 's lymphoma treat reduced toxicity condition regimen follow allogeneic ( sibling unrelated ) bone marrow transplantation . - Determine extent duration acute chronic graft-versus-host disease patient treat regimen . - Determine 100-day overall survival long-term progression-free survival patient treat regimen . - Evaluate feasibility collection molecular chimerism study baseline , day 30 , 100 , 6 month one two year relapse . OUTLINE : This multicenter study . - Conditioning regimen : Patients undergo extracorporeal photopheresis use methoxsalen UV light 2 consecutive day day -7 -4 . Patients receive pentostatin intravenously ( IV ) continuously day -3 -2 undergo total body irradiation day -1 . - Allogeneic bone marrow transplantation : Patients undergo infusion allogeneic bone marrow stem cell day 0 . - Graft-versus-host disease prophylaxis : Patients receive oral IV cyclosporine begin day -1 continue 6 month transplantation , oral mycofenolate mofetil begin day 100 continue 1 year , methotrexate IV day 1 3 . Patients follow day 100 , every 3 month 1 year , every 6 month 2 year , annually 2 year . PROJECTED ACCRUAL : A total 36 patient accrue study within 1.8 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>NonHodgkin 's Hodgkin 's lymphoma relapse follow either course high dose chemotherapy autologous stem cell transplantation . &gt; = 90 day prior transplant . Have suitable human leukocyte antigen ( HLA ) match related bone marrow donor compatible match unrelated bone marrow donor molecular type HLA A , B , C , D , DR. Physically psychologically capable undergo bone marrow transplantation attendant period strict isolation . Age &gt; = 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Be able receive 400 cGy Total Body Irradiation ( TBI ) . Pulmonary function test : Diffusing capacity Transfer factor lung carbon monoxide ( DLCO ) &gt; = 50 % predict , forced expiratory volume 1 second ( FEV1 ) &gt; = 50 % predict . Left ventricular ejection fraction ( LVEF ) least 45 % Multi Gated Acquisition Scan ( MUGA ) echocardiogram . Renal function : creatinine clearance &gt; 50 ml/min . Liver function test : &lt; 3 x Upper Limit Normal ( ULN ) . Liver function test include serum glutamic oxaloacetic transaminase ( SGOT ) ( Aspartate transaminase ( AST ) ) , Serum Glutamic Pyruvate Transaminase ( SGPT ) ( Alanine transaminase ( ALT ) ) , bilirubin . Human immunodeficiency virus positive ( HIV+ ) patient ( test positive P21 antibody HIV ) . Evidence active infection ( received parenteral antibiotic &lt; = 2 week prior registration ) . Pregnant breastfeed woman . Curable therapeutic intervention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>